How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets.
about
Chemical philanthropy: a path forward for antibiotic discovery?Drug discovery beyond the rule of 5 - Opportunities and challenges.MacroEvoLution: A New Method for the Rapid Generation of Novel Scaffold-Diverse Macrocyclic LibrariesComputational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitorsYcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and Function.Flexibility is important for inhibition of the MDM2/p53 protein-protein interaction by cyclic β-hairpins.The forgotten or underestimated relevance of biopharmaceutical-based assessments for the oral absorption studies of oxime reactivators.Tactics for preclinical validation of receptor-binding radiotracers.Structural and conformational determinants of macrocycle cell permeability.Design, synthesis, and evaluation of a novel series of macrocyclic inhibitors of norovirus 3CL protease.Targeting Bacillosamine Biosynthesis in Bacterial Pathogens: Development of Inhibitors to a Bacterial Amino-Sugar Acetyltransferase from Campylobacter jejuni.Concise Synthesis of Tetrazole MacrocycleStereochemistry Balances Cell Permeability and Solubility in the Naturally Derived Phepropeptin Cyclic Peptides.Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).Progress towards the broad use of non-peptide synthetic macrocycles in drug discovery.Interconversion Rates between Conformational States as Rationale for the Membrane Permeability of Cyclosporines.Two-Step Synthesis of Complex Artificial Macrocyclic Compounds.Carbonylation as a novel method for the assembly of pyrazine based oligoamide alpha-helix mimetics.From Peptides to Peptidomimetics: A Strategy Based on the Structural Features of Cyclopropane.Characterization of the Fast and Promiscuous Macrocyclase from Plant PCY1 Enables the Use of Simple Substrates.Design, synthesis and fluorescence property evaluation of blue emitting triazole-linked chromene peptidomimetics.Synthetic fermentation of β-peptide macrocycles by thiadiazole-forming ring-closing reactions.Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations?Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
P2860
Q30489379-423A0436-DC61-4C13-B0FB-AEA2DBBA2560Q36203347-F10D6CFA-0FF7-4993-944D-E8BBDC8D8785Q38656515-EDD3D5C7-BC17-4577-A737-A32F825CBCC3Q38732067-483D16AF-8601-47F4-ACBB-B8FBA70CEDB8Q38751212-DD72A3F0-E074-4CD4-92E3-353CE2DE6C52Q38812479-D10ADFB6-77FD-4D40-8B62-C1EFDA315FD5Q38825239-4BA80E5A-DBB3-414E-B537-F500E431FEC5Q38984519-19B35DBF-058E-456D-9642-7A5C08579831Q39283186-0181FA3F-0295-4DD3-B543-3A7E0638094BQ40390221-81660DFA-BEE9-4A16-AF91-D0EDB2DA6759Q40988449-0B497B0E-722A-42B6-AE4F-7FF9BD9F2B41Q42267846-C5E81675-48EE-424F-B21C-111DB70F3EBAQ42358786-C81B68E9-E660-4488-9E21-75D8DAE63CC4Q47760790-F9317D2F-C0E9-42E5-830F-535779869091Q47849835-5D6D50FE-4774-47B4-8215-D6DE08285D5AQ47881312-01C602C8-2B51-4AE8-A2D3-ABA9DDAAB6ADQ48152859-02E803D3-F9A7-4D53-B86C-DF07D21AB273Q48183478-74F5D40F-3D17-4CE8-B963-55023B9FE3FCQ48250705-D69F8AE4-7533-47BD-BC76-E71429B7895FQ49607196-1C8ED587-1A0C-4D39-9619-8AA61C39C533Q50176114-08BB94CB-05C6-43FE-87D5-A593E3208F21Q55365864-2F2BABCE-A5E5-43DB-9074-5C45AF78ED34Q57489617-CE944727-1631-4911-90A0-EE9B0B0A4000Q58046152-4445423E-DB7B-41DF-90E4-93F28B1352C3
P2860
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets.
@en
type
label
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets.
@en
prefLabel
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets.
@en
P2093
P1476
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
@en
P2093
Doreen Dobritzsch
Jan Kihlberg
P304
P356
10.1021/ACS.JMEDCHEM.5B01286
P407
P50
P577
2015-10-30T00:00:00Z